Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 2/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541572 | 1.00 | PDE2A (0.44) | PDE2AGPR55OGAUGT2B7CTNNB1 | |
| SCHEMBL30687097 | 1.00 | PDE2A (0.44) | PDE2AGPR55OGAUGT2B7CTNNB1 | |
| SCHEMBL26938923 | 1.00 | PDE2A (0.44) | PDE2AGPR55OGAUGT2B7CTNNB1 | |
| SCHEMBL15943248 | 1.00 | PDE2A (0.44) | PDE2AGPR55OGAUGT2B7CTNNB1 | |
| SCHEMBL31085174 | 0.89 | UGT2B7 (0.40) | PDE2AGPR55OGAUGT2B7ACACB | |
| SCHEMBL11433328 | 0.87 | PDE2A (0.44) | PDE2AGPR55OGACTNNB1WNT3A | |
| SCHEMBL23082568 | 0.85 | CTNNB1 (0.41) | PDE2AGPR55OGACTNNB1WNT3A | |
| SCHEMBL15265914 | 0.85 | CTNNB1 (0.41) | PDE2AGPR55OGACTNNB1WNT3A | |
| SCHEMBL879006 | 0.85 | GPR55 (0.45) | PDE2AGPR55OGACTNNB1WNT3A | |
| SCHEMBL9141282 | 0.83 | ALOX15 (0.50) | PDE2AUGT2B7NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4611742-A1 | METHODS OF TREATING CFTR-MEDIATED DISEASES OR DISORDERS | Sionna Therapeutics Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4536655-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Sionna Therapeutics Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119677730-A | Compounds, compositions, and methods of use thereof | 希安纳医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024097227-A1 | METHODS OF TREATING CFTR-MEDIATED DISEASES OR DISORDERS | SIONNA THERAPEUTICS (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097227-A1 | METHODS OF TREATING CFTR-MEDIATED DISEASES OR DISORDERS | SIONNA THERAPEUTICS (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023240267-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240267-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, SLC26A4, PKD2 | PDE2A 94/4885GPR55 1983/4885OGA 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.